Advertisement

Silymarin Treatment in Patients with Cirrhosis of the Liver — a Prospective Study

  • P. Ferenci
  • B. Dragosics
  • H. Dittrich
  • H. Frank
  • H. Lochs
  • H. Pamperl
  • S. Meryn
Conference paper

Abstract

Silymarin is the collective name for the flavolignans silibinin, silidianin and silichristin, extracted from the milk thistle Silybum marianum (L.) gaertneri. This drug was shown to protect experimental animals against various hepatotoxins, including phalloidin [1, 2], α-amanitin [3], carbon tetrachloride [4, 5], thioacetamide [6], and galactosamine [4]. The mechanism by which silymarin exerts its “hepatoprotective” action is under intensive investigation. The antitoxic effects of silymarin against the Amanita phalloides toxins phalloidin and α-amanitin are mediated by the inhibition of the binding of phalloidin to specific receptors on liver cell membranes [7] and by the antagonism to the blocking effects of α-amanitin on RNA polymerase [8–10]. Furthermore, the hepatoprotective properties of silymarin may be related to the inhibition of lipid peroxide formation in liver cells [11] and to changes of physical properties of plasma membranes induced by silymarin, making cells more resistant to osmotic lysis and to the action of detergents [12, 13].

Keywords

Primary Biliary Cirrhosis Alcoholic Cirrhosis Underlying Liver Disease Amanita Phalloides Silymarin Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tuchweber B, Sieck R, Trost W (1979) Prevention by silybin of phalloidin induced acute hepatotoxicity. Toxicol Appl Pharmacol 51: 265–275PubMedCrossRefGoogle Scholar
  2. 2.
    Floersheim GL (1978) Experimentelle Grundlagen zur Therapie von Vergiftungen durch den grünen Knollenblätterpilz(Amanita phalloides). Schweiz Med Wochenschr 108:185–197PubMedGoogle Scholar
  3. 3.
    Hahn G, Lehmann HD, Kürten M, Uebel H, Vogel G (1968) Zur Pharmakologie und Toxikologie von Silymarin, des antiheptotoxischen Wirkprinzipes aus Silybum marianum (L.) Gaertn. Arzneimittelforsch 18: 698–704PubMedGoogle Scholar
  4. 4.
    Rauen HM, Schriewer H (1971) Die antihepatotoxische Wirkung von Silymarin bei experimentellen Leberschädigungen der Ratte durch Tetrachlorkohlenstoff, D-Galaktosamin und Allylalkohol. Arzneimittelforsch 21:1194–1212PubMedGoogle Scholar
  5. 5.
    Rauen HM, Schriewer H (1973) Die antihepatotoxische Wirkung von parenteral verabreichtem Silymarin bei der Leberschädigung der Ratte durch CCI4. Arzneimittelforsch 23:148–149PubMedGoogle Scholar
  6. 6.
    Schriewer H, Badde R, Roth G, Rauen HM (1973) Die antihepatotoxische Wirkung des Sily-marins bei der Leberschädigung durch Thioacetamid. Arzneimittelforsch 23:160–161Google Scholar
  7. 7.
    Lotter HL (1984) Untersuchung der Struktur-Wirkungsbeziehung antihepatotoxischer Naturstoffe (Silybin-Äntamanid) durch Röntgenstrukturanalyse. Z Naturforsch 39 c: 535Google Scholar
  8. 8.
    Sonnenbichler J, Zetl I (1984) Untersuchungen zum Wirkungsmechanismus von Silibinin. V. Einfluß von Silibinin auf die Synthese ribosomaler RNA, mRNA und tRNA in Rattenlebern in vivo. Hoppe Seylers Z Physiol Chem 365: 555–560PubMedCrossRefGoogle Scholar
  9. 9.
    Machicao F, Sonnenbichler J (1977) Mechanism of the stimulation of RNA synthesis in rat liver nuclei by silybin. Hoppe Seylers Z Physiol Chem 358:141–147CrossRefGoogle Scholar
  10. 10.
    Faulstich H (1979) New Aspects of Amanita poisoning. Klin Wochenschr 57:1143–1152PubMedCrossRefGoogle Scholar
  11. 11.
    Bindoli A, Cavallini L, Siliprandi N (1977) Inhibitory action of Silymarin of lipid peroxide formation in rat liver mitochondria and microsomes. Biochem Pharmacol 26: 2405–2409PubMedCrossRefGoogle Scholar
  12. 12.
    Valenzuela A, Barria T, Guerra R, Garrido A (1985) Inhibitory effect of the flavonoid Silymarin on the erythrocyte hemolysis induced by Phenylhydrazine. Biochem Biophys Res Commun 126: 712–715PubMedCrossRefGoogle Scholar
  13. 13.
    Ramellini G, Meldolesi J (1974) Stabilization of isolated rat liver plasma membranes by treatment in vitro with Silymarin. Arzneimittelforsch 24: 806–808PubMedGoogle Scholar
  14. 14.
    Salmi HA, Sarna S (1982) Effect of Silymarin on chemical, functional and morphological alterations of the liver. Scand J Gastroenterol 17: 517–520PubMedCrossRefGoogle Scholar
  15. 15.
    Fintelmann V, Albert A (1980) Nachweis der therapeutischen Wirksamkeit von Legalon® bei toxischen Lebererkrankungen im Doppelblindversuch. Therapiewoche 30: 5589Google Scholar
  16. 16.
    Child CG, Turcotte JG (1964) Surgery and portal hypertension. In: Child CG (ed) The liver and portal hypertension. Saunders, Philadelphia, pp 50–56Google Scholar
  17. 17.
    Ferenci P, Dragosics B, Marosi L, Kiss F (1984) Relative incidence of primary liver cancer in cirrhosis in Austria. Etiological considerations. Liver 4: 7–14PubMedGoogle Scholar
  18. 18.
    Bulles H, Bulles J, Krumbiegel G, Mennicke WH, Nitz D (1975) Untersuchungen zur Verstoffwechselung und zur Ausscheidung von Silybin bei der Ratte. Arzneimittelforsch 25:902–905PubMedGoogle Scholar
  19. 19.
    Cox DR (1972) Regression models and life tables (with discussion). J R Statist Soc [B] 34: 187–220Google Scholar
  20. 20.
    Preisig R (1981) Problems in phase I and phase II trials with “hepatoprotective” drugs. In: Conn HO (ed) International workshop on (+)-cyanidanol-3 in diseases of the liver. Academic, London; Grune & Stratton, New York, pp 41–48 (The Royal Society of Medicine, International congress and symposium series, no 47)Google Scholar
  21. 21.
    Juhl E, Christensen E, Tygstrup N (1977) The epidemiology of the gastrointestinal RCT. N Engl J Med 296: 20–22CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Heidelberg 1987

Authors and Affiliations

  • P. Ferenci
    • 1
  • B. Dragosics
    • 1
  • H. Dittrich
    • 2
  • H. Frank
    • 3
  • H. Lochs
    • 1
  • H. Pamperl
    • 1
  • S. Meryn
    • 1
  1. 1.First Department of Gastroenterology and HepatologyUniversity of ViennaAustria
  2. 2.Ambulatorium Süd der Wiener GebietskrankenkasseViennaAustria
  3. 3.Department of Internal MedicineSophienspitalViennaAustria

Personalised recommendations